Page last updated: 2024-12-10

prostaglandin f1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

prostaglandin F1: was EN to PROSTAGLANDINS F (75-81); RN given refers to (9 alpha,11 alpha,13E,15S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5280939
CHEMBL ID1325783
CHEBI ID28852
SCHEMBL ID1477281
MeSH IDM0262358

Synonyms (60)

Synonym
prostaglandin f1
(13e,15s)-9alpha,11alpha,15-trihydroxyprost-13-en-1-oic acid
prostaglandin f1-alpha
CHEBI:28852 ,
pgf 1-alpha
MLS000069612 ,
smr000058791
cyclopentaneheptanoic acid, 3,5-dihydroxy-2-(3-hydroxy-1-octenyl)-
prostaglandin f1 alpha
prost-13-en-1-oic acid, 9,11,15-trihydroxy-, (9-alpha,11-alpha,13e,15s)
protaglandin f1
IDI1_033962
9s,11r,15s-trihydroxy-13e-prostaenoic acid
pgf1alpha
LMFA03010137
prostaglandin f1.alpha.
prostaglandin f1alpha
745-62-0
(13e,15s)-9alpha,11alpha-9,11,15-trihydroxyprost-13-en-1-oic acid
C06475
prostaglandin f1alpha, synthetic
BSPBIO_001492
NCGC00021875-04
NCGC00021875-03
NCGC00021875-05
HMS1989K14
BML1-F09
HMS1791K14
HMS1361K14
pgf1
7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]cyclopentyl]heptanoic acid
SCHEMBL1477281
HMS2231H22
CHEMBL1325783
unii-wj72o6860w
wj72o6860w ,
prost-13-en-1-oic acid,9,11,15-trihydroxy-, (9a,11a,13e,15s)-
u 18714
gtpl5412
7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(1e,3s)-3-hydroxyoct-1-en-1-yl]cyclopentyl]heptanoic acid
prost-13-en-1-oic acid, 9,11,15-trihydroxy-, (9-.alpha.,11-.alpha.,13e,15s)
HMS3648J19
HMS3402K14
OPERA_ID_1669
prost-13-en-1-oic acid,9,11,15-trihydroxy-,(9a,11a,13e,15s)-
(9alpha,11alpha,13e,15s)-9,11,15-trihydroxyprost-13-en-1-oic acid
9a,11a,15(s)-trihydroxy-13-trans-prostenoate
3,5-dihydroxy-2-(3-hydroxy-1-octenyl)- (8ci)-cyclopentaneheptanoic acid
9a,11a,15(s)-trihydroxy-13-trans-prostenoic acid
3,5-dihydroxy-2-(3-hydroxy-1-octenyl)- (8ci)-cyclopentaneheptanoate
pgf1alpha, prostaglandin f1alpha, powder
(+)-(9alpha,11alpha,13e,15s)-9,11,15-trihydroxyprost-13-en-1-oic acid
7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((s,e)-3-hydroxyoct-1-enyl)cyclopentyl)heptanoic acid
Q27088352
SR-01000946441-1
sr-01000946441
pgf1 alpha (prostaglandin f1 alpha )
DTXSID901339475
AKOS040756112
prostaglandin f1??

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" We studied 34 hypertensive patients, whose blood pressure levels were controlled by Enalapril at a mean dosage of 12."( [The role of prostacyclin and thromboxane in the antihypertensive action of enalapril].
Castillo Ferrando, JR; Garrido Peralta, M; Oliván Martínez, J; Serrano Molina, J; Suárez Morano, J, 1990
)
0.28
" The C6 dose-response curve for release of C20:4 plus its metabolites was monotonic, which indicates dependence on channel formation, whereas the dose-response curve for lysis displayed multi-hit behavior."( Release of arachidonic acid and formation of oxygenated derivatives after complement attack on macrophages: role of channel formation.
Hammer, CH; Imagawa, DK; Koga, PG; Mayer, MM; Osifchin, NE; Ramm, LE; Shin, HS, 1986
)
0.27
" The results showed that dexamethasone treatment did not diminish lung 6-keto-prostaglandin F1 alpha level even at the highest dosage used (12 mg/kg)."( Glucocorticoid and prostaglandin: lack of an inhibitory effect by dexamethasone on the synthesis of 6-ketoprostaglandin F1 alpha in rat lung.
Tsai, MY, 1987
)
0.71
" More detailed dose-response studies revealed that the I50 for inhibition of PG production by dexamethasone was less than 10 nM, thus indicating that the steroid effect probably involved high affinity glucocorticoid receptors."( Prostaglandin production by human trabecular cells: in vitro inhibition by dexamethasone.
Mitchell, MD; Polansky, JR; Weinreb, RN, 1983
)
0.27
"Experiments were performed in pigs to examine the relationship between the effects of various nonsteroid antiinflammatory drugs on gastric (fundic) mucosal content of prostaglandin (PG)E2 and 6-keto-PGF1 alpha, and the development of damage to the fundic mucosa under acute and chronic dosage conditions."( Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production.
Rainsford, KD; Willis, C, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
prostaglandins Falpha
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency31.62280.044717.8581100.0000AID485294
Chain A, CruzipainTrypanosoma cruziPotency25.11890.002014.677939.8107AID1476
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.98330.011212.4002100.0000AID1030
gemininHomo sapiens (human)Potency1.25890.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346448Human CatSper2 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
Progesterone activates the principal Ca2+ channel of human sperm.
AID1346462Human CatSper1 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
Progesterone activates the principal Ca2+ channel of human sperm.
AID1346498Human CatSper4 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
Progesterone activates the principal Ca2+ channel of human sperm.
AID1346536Human CatSper3 (CatSper and Two-Pore channels)2011Nature, Mar-17, Volume: 471, Issue:7338
Progesterone activates the principal Ca2+ channel of human sperm.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID681887TP_TRANSPORTER: inhibition of alaninyl-d4TMP in the presence of Prostaglandin F1alpha at a concentration of 20uM in membrane vesicles from MRP4-expressing Sf9 cells2003Proceedings of the National Academy of Sciences of the United States of America, Aug-05, Volume: 100, Issue:16
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (306)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990156 (50.98)18.7374
1990's89 (29.08)18.2507
2000's32 (10.46)29.6817
2010's25 (8.17)24.3611
2020's4 (1.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.76 (24.57)
Research Supply Index5.81 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (5.03%)5.53%
Reviews5 (1.57%)6.00%
Case Studies2 (0.63%)4.05%
Observational0 (0.00%)0.25%
Other295 (92.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]